Inhibikase Therapeutics, Inc. (IKT)
NASDAQ: IKT · Real-Time Price · USD
1.890
+0.010 (0.53%)
At close: Mar 9, 2026, 4:00 PM EDT
1.890
0.00 (0.00%)
After-hours: Mar 9, 2026, 4:10 PM EDT
Inhibikase Therapeutics Market Cap
Inhibikase Therapeutics has a market cap or net worth of $258.52 million as of March 9, 2026. Its market cap has decreased by -13.19% in one year.
Market Cap
258.52M
Enterprise Value
172.99M
1-Year Change
-13.19%
Ranking
Category
Stock Price
$1.89
Market Cap Chart
Since the IPO on December 23, 2020, Inhibikase Therapeutics's market cap has increased from $100.46M to $258.52M, an increase of 157.34%. That is a compound annual growth rate of 19.92%.
Market Capitalization
Market capitalization, also called net worth, is the total value of all of a company's outstanding shares. It is calculated by multiplying the stock price by the number of shares outstanding.
Formula: Market Cap = Stock Price * Shares Outstanding
Full DefinitionRelated Stocks
| Company | Market Cap |
|---|---|
| Coherus Oncology | 272.04M |
| Enlivex | 270.61M |
| Prelude Therapeutics | 266.14M |
| Cellectis | 265.08M |
| Fennec Pharmaceuticals | 262.98M |
| Abeona Therapeutics | 262.83M |
| Cybin | 262.69M |
| Minerva Neurosciences | 260.08M |